Percent of Office of In Vitro Diagnostics and Radiological Health (OIR) 180-Day PMA Supplements decisions made in 180 days or less during the quarter
Dictionary: Premarket approval (PMA) is the FDA process of scientific and regulatory review to evaluate the safety and effectiveness of Class III medical devices. Class III devices are those that support or sustain human life, are of substantial importance in preventing impairment of human health, or which present a potential, unreasonable risk of illness or injury. PMA is the most stringent type of device marketing application required by FDA. The applicant must receive FDA approval of its PMA application prior to marketing the device. PMA approval is based on a determination by FDA that the PMA contains sufficient valid scientific evidence to assure that the device is safe and effective for its intended use(s).
A 180-day supplement is a request for a significant change in components, materials, design, specification, software, color additive, and labeling to an approved premarket application or premarket report. The measure tracks the number of 180-day PMA Supplements decisions made during the quarter that were within 180 FDA days. It includes only fee-paying 180-day PMA supplements.
Information is current as of September 30, 2013
Fiscal Year - 2011
|Oct – Dec 2010||80||75|
|Jan – Mar 2011||80||100|
|Apr – Jun 2011||80||100|
|Jul – Sep 2011||80||100|
FY 2011 Overall: 90%
Number of OIR 180-Day PMA Supplements decisions made in 180 days or less during the quarter
Fiscal Year - 2011
|Oct – Dec 2010||N/A||6|
|Jan – Mar 2011||N/A||6|
|Apr – Jun 2011||N/A||3|
|Jul – Sep 2011||N/A||3|
FY 2011 Total: 18
Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.